Anti-wolbachia treatment of onchocerciasis in an area co-endemic for loiasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN48118452

Enrollment

180

Registered

2006-01-24

Start date

2003-07-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Onchocerciasis, loiasis Infections and Infestations Onchocerciasis

Interventions

200 mg/day oral doxycycline or matching placebo for six weeks 150 mg/kg oral single dose ivermectin or matching placebo for four months post commencement of doxycycline treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Mean microfilaridermia >10 mf/mg 2. Informed consent

Exclusion criteria

Exclusion criteria: 1. Body weight 50 3. Patients receiving medication for chronic illness 4. Anti-filarial treatment in the last year 5. Alcohol or drug abuse 6. Abnormal renal or hepatic blood chemistry 7. Pregnancy 8. Lactation

Design outcomes

Primary

Measure	Time frame
Sustained amicrofilaridermia in doxycycline or doxycycline and ivermectin-treated patients compared with ivermectin treated-patients assessed by levels of microfilaridermia in skin biopsies at 4, 12 and 21 months	—

Secondary

Measure	Time frame
Macrofilaricidal (curative) effects of doxycycline treatment assessed by ultrasonography, histology and ribonucleic acid (RNA) levels of adult worms in onchocercomas at 21 months	—

Countries

Cameroon

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 31, 2026